DXCM DexCom, Inc.

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...

DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...

DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...

Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.

DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.

Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.

Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.

We all knew it was coming. The expected valuation may surprise, though.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...

DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...

DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Revenue hit $1.31 billion with strong international growth and margin expansion.

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom’s fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This move lines up with recent analyst commentary, where many firms are reaffirming or raising targets, while a smaller group trims expectations on valuation concerns and growth assumptions. As you read on, you will see how these price target adjustments fit into the broader DexCom narrative and what to watch to stay aligned with the...

In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, implying around 11–13% growth. Beyond the headline numbers, DexCom highlighted progress in expanding access for type 2 diabetes patients not using insulin and advancing next-generation sensors, underlining its push into broader metabolic health monitoring. We’ll now look at how DexCom’s raised 2026...

Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July.

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter results and slightly raised its full-year financial outlook.

DexCom Inc (DXCM) delivered 13% revenue growth and raised full-year guidance, driven by strong international performance and improved margins.

Revenue hit $1.31 billion with strong international growth and margin expansion.

Moby summary of DexCom, Inc.'s Q2 2026 earnings call

DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets. Worldwide revenue totaled $1.31 billion, co